Highest development stage: Phase 1

Development status: Inactive

Gram-negative activity

Mechanism of Action/Target pathogen: Was in trials for treatment of MRSA and nosocomial infections

Reason dropped: In phase I trials, QT elongation was seen in patients so was dropped for safety reasons (2)

Additional information: Levasseur P, Delachaume C, Lowther J, Hodgson J. Minimum inhibitory concentrations and mutation prevention concentrations of NXL101, a novel topoisomerase IV inhibitor, against Staphylococcus aureus including multi-resistant strains. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;184